

May 25, 2018

The Manager - Listing

**BSE Limited**

Corporate Relationship Dept., 1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

Dear Sir(s),

**Sub: Reconciliation of Equity**

**Ref: Email and NSE Letter NSE/LIST/FR/5931 dated May 22, 2018 for submission of  
Standalone Reconciliation of Equity**

**Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN**

With reference to financial results submitted by the Company on May 21, 2018 and in further reference to NSE's email and letter as stated above, we enclose the Standalone Reconciliation of Equity.

We request you to kindly take the same on record.

Thanking you,

**For AstraZeneca Pharma India Limited**



Pratap Rudra  
Company Secretary & Legal Counsel

**AstraZeneca Pharma India Limited**  
**Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045**

The reconciliation of Total Equity (Shareholder's Funds) reported in accordance with Indian GAAP and Total Equity reported in accordance with Ind AS is given below:

Particulars	Rs. in lakhs
	As at 31 March, 2017
Equity under Previous GAAP	18,045.66
<b>Adjustments:</b>	
Provision for expected credit loss	(59.81)
Reversal of rent equalisation reserve	107.11
Employee stock compensation plan	299.73
Deferred tax asset	4,021.71
Others	(127.59)
<b>Total Equity as per Ind AS</b>	<b>22,286.81</b>

For AstraZeneca Pharma India Limited

  
**Gagan Singh Bedi**  
Managing Director

Vaidish